Cytochrome P450 1B1 and 2C9 genotypes and risk of ischemic vascular disease, cancer, and chronic obstructive pulmonary disease

Current Vascular Pharmacology

Volumn 10, Issue 4, 2012, Pages 512-520

  Kaur Knudsen, Diljit ^a,c   Bojesen, Stig E ^a,b,c   Nordestgaard, Børge G ^a,b,c  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Mental Health Center Glostrup   (Denmark)

Author keywords

17 estradiol; Arachidonic acid; CYP1B1; CYP2C9; General population; Polycyclic aromatic hydrocarbons; Single nucleotide polymorphism; Tobacco

Indexed keywords

ARACHIDONIC ACID; ASPARAGINE; CYTOCHROME P450 1B1; CYTOCHROME P450 2C9; ESTRADIOL; ESTROGEN; ISOLEUCINE; LEUCINE; POLYCYCLIC AROMATIC HYDROCARBON; TOBACCO SMOKE; VALINE;

AMINO ACID METABOLISM; BREAST CANCER; BREAST EPITHELIUM; CANCER RISK; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE ASSOCIATION; DNA POLYMORPHISM; ENDOMETRIUM; ENDOMETRIUM CANCER; ENZYME ACTIVITY; GENETIC CODE; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HEART PROTECTION; HETEROZYGOTE; HOMOZYGOTE; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; LARYNX CANCER; LUNG CANCER; META ANALYSIS (TOPIC); NEOPLASM; OVARY CANCER; PROTEIN BINDING; PROTEIN INTERACTION; REVIEW; RISK FACTOR; SMOKING; TOBACCO; VASCULAR DISEASE;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; EICOSANOIDS; ESTROGENS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ISCHEMIA; MALE; METABOLIC DETOXICATION, PHASE I; NEOPLASMS; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SMOKING; VASCULAR DISEASES;

EID: 84861682812     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112800812746     Document Type: Review

References (86)

1. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360: 1155-62.
2. Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des 2010; 16: 204-19.
3. Ioannides C, Lewis DF. Cytochromes P450 in the bioactivation of chemicals. Curr Top Med Chem 2004; 4: 1767-88.
4. Shimada T, Oda Y, Gillam EM, Guengerich FP, Inoue K. Metabolic activation of polycyclic aromatic hydrocarbons and other procarcinogens by cytochromes P450 1A1 and P450 1B1 allelic variants and other human cytochromes P450 in Salmonella typhimurium NM2009. Drug Metab Dispos 2001; 29: 1176-82.
5. Shimada T, Hayes CL, Yamazaki H, et al. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res 1996; 56: 2979-84.
6. Shou M, Krausz KW, Gonzalez FJ, Gelboin HV. Metabolic activation of the potent carcinogen dibenzo[a, h]anthracene by cDNA-expressed human cytochromes P450. Arch Biochem Biophys 1996; 328: 201-7.
7. Hayes CL, Spink DC, Spink BC, et al. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 1996; 93: 9776-81.
8. Shimada T, Watanabe J, Kawajiri K, et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 1999; 20: 1607-13.
9. Theken KN, Lee CR. Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics 2007; 8: 1369-83.
10. Ingelman-Sundberg M. Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 2004; 369: 89-104.
11. http://www.cypalleles.ki.se/cyp1b1.htm. 2011. Ref Type: Generic
12. http://drnelson.uthsc.edu/cytochromeP450.html. 2011. Ref Type: Generic
13. Hanna IH, Dawling S, Roodi N, Guengerich FP, Parl FF. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res 2000; 60: 3440-4.
14. Kaur-Knudsen D, Nordestgaard BG, Tybjaerg-Hansen A, Bojesen SE. CYP1B1 genotype and risk of cardiovascular disease, pulmonary disease, and cancer in 50,000 individuals. Pharmacogenet Genomics 2009; 19: 685-94.
15. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999; 353: 717-9.
16. Takanashi K, Tainaka H, Kobayashi K, et al. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 2000; 10: 95-104.
17. Kaur-Knudsen D, Nordestgaard BG, Bojesen SE. CYP2C9 genotype does not affect risk of tobacco-related cancer in the general population. Cancer Epidemiol 2010; 34: 178-83.
18. Ding YS, Ashley DL, Watson CH. Determination of 10 carcinogenic polycyclic aromatic hydrocarbons in mainstream cigarette smoke. J Agric Food Chem 2007; 55: 5966-73.
19. Boffetta P, Jourenkova N, Gustavsson P. Cancer risk from occupational and environmental exposure to polycyclic aromatic hydrocarbons. Cancer Causes Control 1997; 8: 444-72.
20. Mastrangelo G, Fadda E, Marzia V. Polycyclic aromatic hydrocarbons and cancer in man. Environ Health Perspect 1996; 104: 1166-70.
21. Donnan GA, McNeil JJ, Adena MA, et al. Smoking as a risk factor for cerebral ischaemia. Lancet 1989; 2: 643-7.
22. Rigotti NA, Pasternak RC. Cigarette smoking and coronary heart disease: risks and management. Cardiol Clin 1996; 14: 51-68.
23. Burstyn I, Kromhout H, Partanen T, et al. Polycyclic aromatic hydrocarbons and fatal ischemic heart disease. Epidemiology 2005; 16: 744-50.
24. Ramos KS, Moorthy B. Bioactivation of polycyclic aromatic hydrocarbon carcinogens within the vascular wall: implications for human atherogenesis. Drug Metab Rev 2005; 37: 595-610.
25. Curfs DM, Knaapen AM, Pachen DM, et al. Polycyclic aromatic hydrocarbons induce an inflammatory atherosclerotic plaque phenotype irrespective of their DNA binding properties. FASEB J 2005; 19: 1290-2.
26. Knaapen AM, Curfs DM, Pachen DM, et al. The environmental carcinogen benzo[a]pyrene induces expression of monocytechemoattractant protein-1 in vascular tissue: a possible role in atherogenesis. Mutat Res 2007; 621: 31-41.
27. Clinton GM, Hua W. Estrogen action in human ovarian cancer. Crit Rev Oncol Hematol 1997; 25: 1-9.
28. Henderson BE, Feigelson HS. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427-33.
29. Persson I. Estrogens in the causation of breast, endometrial and ovarian cancers-evidence and hypotheses from epidemiological findings. J Steroid Biochem Mol Biol 2000; 74: 357-64.
30. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett 2005; 227: 115-24.
31. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998; 19: 1-27.
32. Downie D, McFadyen MC, Rooney PH, et al. Profiling cytochrome P450 expression in ovarian cancer: identification of prognostic markers. Clin Cancer Res 2005; 11: 7369-75.
33. Murray GI, Taylor MC, McFadyen MC, et al. Tumor-specific expression of cytochrome P450 CYP1B1. Cancer Res 1997; 57: 3026-31.
34. Saini S, Hirata H, Majid S, Dahiya R. Functional significance of cytochrome P450 1B1 in endometrial carcinogenesis. Cancer Res 2009; 69: 7038-45.
35. Oltman CL, Weintraub NL, VanRollins M, Dellsperger KC. Epoxyeicosatrienoic acids and dihydroxyeicosatrienoic acids are potent vasodilators in the canine coronary microcirculation. Circ Res 1998; 83: 932-9.
36. Yuhki K, Kojima F, Kashiwagi H, et al. Roles of prostanoids in the pathogenesis of cardiovascular diseases: Novel insights from knockout mouse studies. Pharmacol Ther 2011; 129: 195-205.
37. Zhao L, Funk CD. Lipoxygenase pathways in atherogenesis. Trends Cardiovasc Med 2004; 14: 191-5.
38. Daikh BE, Lasker JM, Raucy JL, Koop DR. Regio-and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9. J Pharmacol Exp Ther 1994; 271: 1427-33.
39. Li N, Liu JY, Qiu H, et al. Use of metabolomic profiling in the study of arachidonic acid metabolism in cardiovascular disease. Congest Heart Fail 2011; 17: 42-6.
40. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science 1999; 285: 1276-9.
41. Seubert JM, Sinal CJ, Graves J, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res 2006; 99: 442-50.
42. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004; 52: 447-54.
43. Fer M, Dreano Y, Lucas D, et al. Metabolism of eicosapentaenoic and docosahexaenoic acids by recombinant human cytochromes P450. Arch Biochem Biophys 2008; 471: 116-25.
44. Murray GI, Melvin WT, Greenlee WF, Burke MD. Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 2001; 41: 297-316.
45. Cote ML, Wenzlaff AS, Bock CH, et al. Combinations of cytochrome P-450 genotypes and risk of early-onset lung cancer in Caucasians and African Americans: a population-based study. Lung Cancer 2007; 55: 255-62.
46. Cote ML, Yoo W, Wenzlaff AS, et al. Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women. Carcinogenesis 2009; 30: 626-35.
47. Liang G, Pu Y, Yin L. Rapid detection of single nucleotide polymorphisms related with lung cancer susceptibility of Chinese population. Cancer Lett 2005; 223: 265-74.
48. Shah PP, Singh AP, Singh M, et al. Association of functionally important polymorphisms in cytochrome P4501B1 with lung cancer. Mutat Res 2008; 643: 4-10.
49. Sorensen M, Autrup H, Tjonneland A, Overvad K, Raaschou-Nielsen O. Genetic polymorphisms in CYP1B1, GSTA1, NQO1 and NAT2 and the risk of lung cancer. Cancer Lett 2005; 221: 185-90.
50. Timofeeva MN, Kropp S, Sauter W, et al. CYP450 polymorphisms as risk factors for early-onset lung cancer: gender-specific differences. Carcinogenesis 2009; 30: 1161-9.
51. Watanabe J, Shimada T, Gillam EM, et al. Association of CYP1B1 genetic polymorphism with incidence to breast and lung cancer. Pharmacogenetics 2000; 10: 25-33.
52. Wenzlaff AS, Cote ML, Bock CH, et al. CYP1A1 and CYP1B1 polymorphisms and risk of lung cancer among never smokers: a population-based study. Carcinogenesis 2005; 26: 2207-12.
53. Yoon KA, Kim JH, Gil HJ, et al. CYP1B1, CYP1A1, MPO, and GSTP1 polymorphisms and lung cancer risk in never-smoking Korean women. Lung Cancer 2008; 60: 40-6.
54. Chen B, Qiu LX, Li Y, et al. The CYP1B1 Leu432Val polymorphism contributes to lung cancer risk: evidence from 6501 subjects. Lung Cancer 2010; 70: 247-52.
55. Harth V, Schafer M, Abel J, et al. Head and neck squamous-cell cancer and its association with polymorphic enzymes of xenobiotic metabolism and repair. J Toxicol Environ Health A 2008; 71: 887-97.
56. Ko Y, Abel J, Harth V, et al. Association of CYP1B1 codon 432 mutant allele in head and neck squamous cell cancer is reflected by somatic mutations of p53 in tumor tissue. Cancer Res 2001; 61: 4398-404.
57. Hung RJ, Boffetta P, Brennan P, et al. GST, NAT, SULT1A1, CYP1B1 genetic polymorphisms, interactions with environmental exposures and bladder cancer risk in a high-risk population. Int J Cancer 2004; 110: 598-604.
58. Singh AP, Shah PP, Mathur N, et al. Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer. Mutat Res 2008; 639: 11-9.
59. Zienolddiny S, Campa D, Lind H, et al. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis 2008; 29: 1164-9.
60. Le MN, Orlowski E, Schenker MB, et al. Occupational exposures estimated by means of job exposure matrices in relation to lung function in the PAARC survey. Occup Environ Med 1995; 52: 634-43.
61. Paracchini V, Raimondi S, Gram IT, et al. Meta-and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am J Epidemiol 2007; 165: 115-25.
62. Yao L, Fang F, Wu Q, Zhong Y, Yu L. No association between CYP1B1 Val432Leu polymorphism and breast cancer risk: a metaanalysis involving 40,303 subjects. Breast Cancer Res Treat 2010; 122: 237-42.
63. Economopoulos KP, Sergentanis TN. Three polymorphisms in cytochrome P450 1B1 (CYP1B1) gene and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2010; 122: 545-51.
64. Wang F, Zou YF, Sun GP, Su H, Huang F. Association of CYP1B1 gene polymorphisms with susceptibility to endometrial cancer: a meta-analysis. Eur J Cancer Prev 2011; 20: 112-20.
65. Bandiera S, Weidlich S, Harth V, et al. Proteasomal degradation of human CYP1B1: effect of the Asn453Ser polymorphism on the post-translational regulation of CYP1B1 expression. Mol Pharmacol 2005; 67: 435-43.
66. Delort L, Chalabi N, Satih S, et al. Association between genetic polymorphisms and ovarian cancer risk. Anticancer Res 2008; 28: 3079-81.
67. Goodman MT, McDuffie K, Kolonel LN, et al. Case-control study of ovarian cancer and polymorphisms in genes involved in catecholestrogen formation and metabolism. Cancer Epidemiol Biomarkers Prev 2001; 10: 209-16.
68. Holt SK, Rossing MA, Malone KE, et al. Ovarian cancer risk and polymorphisms involved in estrogen catabolism. Cancer Epidemiol Biomarkers Prev 2007; 16: 481-9.
69. Sellers TA, Schildkraut JM, Pankratz VS, et al. Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2536-43.
70. The Health Consequences of Smoking, A Report to the Surgeon General. Washington, D. C.: U.S. Department of Health and Human Services, 2004, pp. 1-921.
71. Rokitta D, Fuhr U. Comparison of enzyme kinetic parameters obtained in vitro for reactions mediated by human CYP2C enzymes including major CYP2C9 variants. Curr Drug Metab 2010; 11: 153-61.
72. Sano E, Li W, Yuki H, et al. Mechanism of the decrease in catalytic activity of human cytochrome P450 2C9 polymorphic variants investigated by computational analysis. J Comput Chem 2010; 31: 2746-58.
73. Garcia-Martin E, Martinez C, Ladero JM, et al. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk. Cancer Lett 2002; 180: 41-6.
74. London SJ, Daly AK, Leathart JB, Navidi WC, Idle JR. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics 1996; 6: 527-33.
75. London SJ, Sullivan-Klose T, Daly AK, Idle JR. Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics 1997; 7: 401-4.
76. Fortuny J, Kogevinas M, Garcia-Closas M, et al. Use of analgesics and non-steroidal anti-inflammatory drugs, genetic predisposition, and bladder cancer risk in Spain. Cancer Epidemiol Biomarkers Prev 2006; 15: 1696-702.
77. Wen H, Ding Q, Fang ZJ, Xia GW, Fang J. Population study of genetic polymorphisms and superficial bladder cancer risk in Han-Chinese smokers in Shanghai. Int Urol Nephrol 2009; 41: 855-64.
78. Kaur-Knudsen D, Bojesen SE, Nordestgaard BG. Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. Pharmacogenomics J 2009; 9: 327-32.
79. Funk M, Freitag R, Endler G, et al. Influence of cytochrome P450 2C9*2 and 2C9*3 variants on the risk of ischemic stroke: a crosssectional case-control study. Clin Chem 2005; 51: 1716-8.
80. Haschke-Becher E, Kirchheiner J, Trummer O, et al. Impact of CYP2C8 and 2C9 polymorphisms on coronary artery disease and myocardial infarction in the LURIC cohort. Pharmacogenomics 2010; 11: 1359-65.
81. Marciante KD, Totah RA, Heckbert SR, et al. Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenet Genomics 2008; 18: 535-43.
82. Morgan TM, Krumholz HM, Lifton RP, Spertus JA. Nonvalidation of reported genetic risk factors for acute coronary syndrome in a large-scale replication study. JAMA 2007; 297: 1551-61.
83. Ercan B, Ayaz L, Cicek D, Tamer L. Role of CYP2C9 and CYP2C19 polymorphisms in patients with atherosclerosis. Cell Biochem Funct 2008; 26: 309-13.
84. Funk M, Endler G, Freitag R, et al. CYP2C9*2 and CYP2C9*3 alleles confer a lower risk for myocardial infarction. Clin Chem 2004; 50: 2395-8.
85. Visser LE, van Schaik RH, Jan Danser AH, et al. The risk of myocardial infarction in patients with reduced activity of cytochrome P450 2C9. Pharmacogenet Genomics 2007; 17: 473-9.
86. Yasar U, Bennet AM, Eliasson E, et al. Allelic variants of cytochromes P450 2C modify the risk for acute myocardial infarction. Pharmacogenetics 2003; 13: 715-20.